Dilip Shanghvi is not one for flamboyant statements or headline-grabbing moves. Yet, over the decades, the soft-spoken ...

Sun Pharma disclosed that supplies to the US from the Halol facility contributed to 3% of consolidated revenues in FY22, which translates into $150-160 million in sales, or approximately 30% of US ...

The companies behind the product pulls are Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, all three of which hail from India. The drugmakers are recalling seizure treatments ...

Indian pharma stocks, including Sun Pharmaceutical Industries, Gland Pharma, Lupin and others traded sharply lower on Wednesday after the US President Donald Trump said he will soon announce a ...

The US Food and Drug Administration (USFDA) has said Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues. In its latest Enforcement Report ...

Global brokerage firm HSBC Global Research, in its latest report, cut its target price on Sun Pharmaceutical Industries ... FDA clearance of GMP issues at its Halol plant, and an improved pace ...

Ajanta Pharma, Granules India, and Sun Pharmaceutical also traded with losses, ranging between 2% and 4%. Uncertainty surrounding the scale of US tariffs, the possibility of retaliatory measures ...